Kevin Sandeman

About

Kevin Sandeman is a leading researcher at the intersection of artificial intelligence and clinical oncology, with a primary focus on improving prostate cancer diagnostics and prognostics. His major contributions center on integrating AI and multiparametric MRI (mpMRI) into established clinical workflows to enhance predictive accuracy. In his highly cited 2022 study (19 citations), Sandeman developed an AI algorithm for prostate cancer detection and grading on biopsy slides, validated on a large cohort of over 4,200 slides from HUS Helsinki University Hospital, demonstrating its potential for real-world clinical diagnostics. Earlier, his 2020 work (17 citations) showed that adding preoperative prostate MRI to standard nomograms (CAPRA, MSKCC, Partin) significantly improved the prediction of adverse pathology and biochemical recurrence after radical prostatectomy. These contributions have direct implications for personalized treatment planning, helping to reduce overtreatment and better stratify patient risk. Sandeman’s research is notable for its translational impact, bridging advanced computational methods with practical urological decision-making, and his work continues to shape how clinicians leverage imaging and AI to predict cancer outcomes.

Research Focus

Key Achievements

Top Papers

1. 1
   AI Model for Prostate Biopsies Predicts Cancer Survival

   19 citations · 2022
2. 2
   Prostate MRI added to CAPRA, MSKCC and Partin cancer nomograms significantly enhances the prediction of adverse findings and biochemical recurrence after radical prostatectomy

   17 citations · 2020

Key Collaborators

Contact & Links